TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: LCNI-6. A Single-centre Intervention Trial in Rural Malawi, Testing the Efficacy of Fortified Spread or Maize-soy Flour Supplementation to Alleviate Moderate Malnutrition Among 6-18 Month Old Children
Brief Summary: This study tests the hypothesis that moderately underweight but not severely wasted 6-17-month old infants receiving fortified spread or maize-soy flour as a food supplement for 12 weeks grow better during the supplementation than infants who do not get any food supplement.


Options:
A: Arm Label: Pushti Packet; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Pushti packet | Arm Label: Rice based Ready to Use Complementary Food Supplements; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Rice based Ready to Use Complementary Food Supplements | Arm Label: Chick-pea based Ready to Use Complementary Food Supplements; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Chick-pea based Ready to Use Complementary Food Supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: Pushti packet; Assigned to Arm(s): Pushti Packet | Intervention Type: DIETARY_SUPPLEMENT; Name: Rice based Ready to Use Complementary Food Supplements; Assigned to Arm(s): Rice based Ready to Use Complementary Food Supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: Chick-pea based Ready to Use Complementary Food Supplements; Assigned to Arm(s): Chick-pea based Ready to Use Complementary Food Supplements
B: Intervention Type: DIETARY_SUPPLEMENT; Name: No food supplement; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement: fortified spread; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement: maize-soy flour; Assigned to Arm(s): N/A
C: Arm Label: Food-for-Training component; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Food-for-Training | Arm Label: Food-for-Training + RUF (Plumpy Doz(r)); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Plumpy Doz(r) - Ready-to-Use Food, Behavioral: Food-for-Training | Intervention Type: DIETARY_SUPPLEMENT; Name: Plumpy Doz(r) - Ready-to-Use Food; Assigned to Arm(s): Food-for-Training + RUF (Plumpy Doz(r)) | Intervention Type: BEHAVIORAL; Name: Food-for-Training; Assigned to Arm(s): Food-for-Training + RUF (Plumpy Doz(r)), Food-for-Training component
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Child's health and nutrition topics | Arm Label: PROMIS intervention; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Small-Quantity Lipid-based nutrient supplement, Behavioral: Child's health and nutrition topics | Intervention Type: DIETARY_SUPPLEMENT; Name: Small-Quantity Lipid-based nutrient supplement; Assigned to Arm(s): PROMIS intervention | Intervention Type: BEHAVIORAL; Name: Child's health and nutrition topics; Assigned to Arm(s): Control, PROMIS intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: LCNI-6. A Single-centre Intervention Trial in Rural Malawi, Testing the Efficacy of Fortified Spread or Maize-soy Flour Supplementation to Alleviate Moderate Malnutrition Among 6-18 Month Old Children
Brief Summary: This study tests the hypothesis that moderately underweight but not severely wasted 6-17-month old infants receiving fortified spread or maize-soy flour as a food supplement for 12 weeks grow better during the supplementation than infants who do not get any food supplement.


Options:
A: N/A
B: Intervention Type: DIETARY_SUPPLEMENT; Name: No food supplement; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement: fortified spread; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement: maize-soy flour; Assigned to Arm(s): N/A
C: Arm Label: Comprehensive; Type: EXPERIMENTAL; Interventions: Dietary Supplement: LNS-PLW, Dietary Supplement: LNS-Child | Arm Label: Child-only LNS; Type: EXPERIMENTAL; Interventions: Dietary Supplement: LNS-Child, Dietary Supplement: IFA | Arm Label: Child-only MNP; Type: EXPERIMENTAL; Interventions: Dietary Supplement: MNP, Dietary Supplement: IFA | Arm Label: Control: IFA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: IFA | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-PLW; Assigned to Arm(s): Comprehensive | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-Child; Assigned to Arm(s): Child-only LNS, Comprehensive | Intervention Type: DIETARY_SUPPLEMENT; Name: MNP; Assigned to Arm(s): Child-only MNP | Intervention Type: DIETARY_SUPPLEMENT; Name: IFA; Assigned to Arm(s): Child-only LNS, Child-only MNP, Control: IFA
D: Intervention Type: DIETARY_SUPPLEMENT; Name: fortified spread (RUTF); Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: maize and soy flour; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: LCNI-6. A Single-centre Intervention Trial in Rural Malawi, Testing the Efficacy of Fortified Spread or Maize-soy Flour Supplementation to Alleviate Moderate Malnutrition Among 6-18 Month Old Children
Brief Summary: This study tests the hypothesis that moderately underweight but not severely wasted 6-17-month old infants receiving fortified spread or maize-soy flour as a food supplement for 12 weeks grow better during the supplementation than infants who do not get any food supplement.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: No food supplement; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement: fortified spread; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement: maize-soy flour; Assigned to Arm(s): N/A
B: Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyNut; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyDoz; Assigned to Arm(s): N/A
C: Arm Label: Food-for-Training component; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Food-for-Training | Arm Label: Food-for-Training + RUF (Plumpy Doz(r)); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Plumpy Doz(r) - Ready-to-Use Food, Behavioral: Food-for-Training | Intervention Type: DIETARY_SUPPLEMENT; Name: Plumpy Doz(r) - Ready-to-Use Food; Assigned to Arm(s): Food-for-Training + RUF (Plumpy Doz(r)) | Intervention Type: BEHAVIORAL; Name: Food-for-Training; Assigned to Arm(s): Food-for-Training + RUF (Plumpy Doz(r)), Food-for-Training component
D: Arm Label: MSPP Integrated Package; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nutributter 3 Months, Integrated Package; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutributter Program, Other: Integrated Package | Arm Label: Nutributter 6 Months, Integrated Package; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutributter Program, Other: Integrated Package | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutributter Program; Assigned to Arm(s): Nutributter 3 Months, Integrated Package, Nutributter 6 Months, Integrated Package | Intervention Type: OTHER; Name: Integrated Package; Assigned to Arm(s): Nutributter 3 Months, Integrated Package, Nutributter 6 Months, Integrated Package

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Double-Blind, Multi-Center Trial of Low Dose Vasopressin Versus Placebo in Traumatic Shock Resuscitation
Brief Summary: Hypothesis: We hypothesize that resuscitation regimens which minimize the total volume of resuscitation fluid, while restoring organ perfusion, will lead to lower morbidity and mortality in critically ill patients following trauma.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Early Goal Directed Therapy (EGDT) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Protocolized Standard Care (PSC) | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual Care (UC) | Intervention Type: PROCEDURE; Name: Early Goal Directed Therapy (EGDT); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Protocolized Standard Care (PSC); Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Usual Care (UC); Assigned to Arm(s): 3
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: vasopressin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: normal saline control | Intervention Type: DRUG; Name: normal saline control; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: vasopressin; Assigned to Arm(s): I
C: Arm Label: continuous terlipressin; Type: EXPERIMENTAL; Interventions: Drug: continuous infusion of terlipressin | Arm Label: vasopressin; Type: EXPERIMENTAL; Interventions: Drug: Arginine vasopressin | Arm Label: terlipressin bolus dose; Type: EXPERIMENTAL; Interventions: Drug: terlipressin bolus administration | Intervention Type: DRUG; Name: continuous infusion of terlipressin; Assigned to Arm(s): continuous terlipressin | Intervention Type: DRUG; Name: Arginine vasopressin; Assigned to Arm(s): vasopressin | Intervention Type: DRUG; Name: terlipressin bolus administration; Assigned to Arm(s): terlipressin bolus dose
D: Arm Label: Angiotensin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Angiotensin II | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Angiotensin II | Intervention Type: DRUG; Name: Angiotensin II; Assigned to Arm(s): Angiotensin, Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants
Brief Summary: This study is planned to evaluate the safety (in terms of occurrence of any serious adverse events), reactogenicity (any side effects) and immunogenicity (ability of the vaccine to develop antibodies that fight infection) of the HRV vaccine when used in pre-term infants aged between 6 and 14 weeks at the time of the first dose in Portugal, France and Poland and in pre-term infants aged between 6 and 12 weeks at the time of first dose in Spain. The study will be performed in four European countries (France, Poland, Spain, and Portugal). The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Intervention Type: BIOLOGICAL; Name: RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2
B: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
C: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
D: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants
Brief Summary: This study is planned to evaluate the safety (in terms of occurrence of any serious adverse events), reactogenicity (any side effects) and immunogenicity (ability of the vaccine to develop antibodies that fight infection) of the HRV vaccine when used in pre-term infants aged between 6 and 14 weeks at the time of the first dose in Portugal, France and Poland and in pre-term infants aged between 6 and 12 weeks at the time of first dose in Spain. The study will be performed in four European countries (France, Poland, Spain, and Portugal). The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Intervention Type: BIOLOGICAL; Name: Live attenuated human rotavirus vaccine; Assigned to Arm(s): N/A
B: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
C: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix, Biological: Tritanrix-HB+Hib, Biological: Polio Sabin | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Tritanrix-HB+Hib, Biological: Polio Sabin | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Tritanrix-HB+Hib; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Polio Sabin; Assigned to Arm(s): Placebo Group, Rotarix Group
D: Intervention Type: BIOLOGICAL; Name: HRV vaccine; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants
Brief Summary: This study is planned to evaluate the safety (in terms of occurrence of any serious adverse events), reactogenicity (any side effects) and immunogenicity (ability of the vaccine to develop antibodies that fight infection) of the HRV vaccine when used in pre-term infants aged between 6 and 14 weeks at the time of the first dose in Portugal, France and Poland and in pre-term infants aged between 6 and 12 weeks at the time of first dose in Spain. The study will be performed in four European countries (France, Poland, Spain, and Portugal). The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
B: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' liquid human rotavirus vaccine 444563, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' liquid human rotavirus vaccine 444563; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Infanrix™; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV); Assigned to Arm(s): Placebo Group, Rotarix Group
C: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix TM | Intervention Type: BIOLOGICAL; Name: Rotarix TM; Assigned to Arm(s): Rotarix Group
D: Arm Label: Rotavin; Type: EXPERIMENTAL; Interventions: Drug: Rotavin | Intervention Type: DRUG; Name: Rotavin; Assigned to Arm(s): Rotavin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Multi-center, Phase II/III Study on Treatment With ABR-217620/Naptumomab Estafenatox Combined With IFN-alpha vs. IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma.
Brief Summary: The drug ABR-217620/naptumomab estafenatox is a fusion of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system. This results in an accumulation of white blood cells in the cancer that can fight the cancer. This study will compare the safety and effectiveness (assessed by tumor status and survival) of ABR-217620/naptumomab estafenatox when given with standard therapy IFN-alpha to IFN-alpha alone in patients with advanced renal cell carcinoma (RCC).


Options:
A: Arm Label: Safety group; Type: EXPERIMENTAL; Interventions: Drug: ABR-217620/naptumomab estafenatox, Drug: IFN-alpha | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ABR-217620/naptumomab estafenatox, Drug: IFN-alpha | Arm Label: 2; Type: OTHER; Interventions: Drug: IFN-alpha | Intervention Type: DRUG; Name: ABR-217620/naptumomab estafenatox; Assigned to Arm(s): 1, Safety group | Intervention Type: DRUG; Name: IFN-alpha; Assigned to Arm(s): 1, 2, Safety group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Temsirolimus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon-Alfa 9MU | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Interferon-Alfa 9MU; Assigned to Arm(s): 2
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus, Drug: Bevacizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon alpha-2a | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon alpha-2a; Assigned to Arm(s): C
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Axitinib (AG-013736) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Axitinib (AG-013736); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strategies for Transfusion of Platelets (SToP) [Formerly Titled "Evaluation of the Hemostatic Efficacy and Platelet Utilization Rates of Low Versus Standard Dose Platelet Therapy"]
Brief Summary: To evaluate the hemostatic efficacy of a low dose platelet transfusion strategy compared to a standard dose platelet transfusion strategy.


Options:
A: Intervention Type: PROCEDURE; Name: low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lower Dose Prophylactic Platelet Transfusions | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Medium Dose Prophylactic Platelet Transfusions | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Higher Dose Prophylactic Platelet Transfusions | Intervention Type: PROCEDURE; Name: Medium Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Lower Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Higher Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 3
C: Intervention Type: PROCEDURE; Name: central venous catheter application; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Therapeutic platelet transfusion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Prophylactic platelet transfusion | Intervention Type: BIOLOGICAL; Name: Prophylactic platelet transfusion; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Therapeutic platelet transfusion; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strategies for Transfusion of Platelets (SToP) [Formerly Titled "Evaluation of the Hemostatic Efficacy and Platelet Utilization Rates of Low Versus Standard Dose Platelet Therapy"]
Brief Summary: To evaluate the hemostatic efficacy of a low dose platelet transfusion strategy compared to a standard dose platelet transfusion strategy.


Options:
A: Intervention Type: PROCEDURE; Name: low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9); Assigned to Arm(s): N/A
B: Arm Label: Eltrombopag; Type: EXPERIMENTAL; Interventions: Drug: Eltrombopag | Intervention Type: DRUG; Name: Eltrombopag; Assigned to Arm(s): Eltrombopag
C: Arm Label: Part A: 300 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 700 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1000 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1500 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC QW; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim IV Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Intervention Type: DRUG; Name: Romiplostim; Assigned to Arm(s): Part A: 1000 µg romiplostim, Part A: 1500 µg romiplostim, Part A: 300 µg romiplostim, Part A: 700 µg romiplostim, Part B: 750 µg romiplostim IV Q2W, Part B: 750 µg romiplostim SC Q2W, Part B: 750 µg romiplostim SC QW
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lower Dose Prophylactic Platelet Transfusions | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Medium Dose Prophylactic Platelet Transfusions | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Higher Dose Prophylactic Platelet Transfusions | Intervention Type: PROCEDURE; Name: Medium Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Lower Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Higher Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 3

Answer: A